U.S. FDA gives first-ever approval to fecal transplant therapy

Follow us on Google News:
 U.S. FDA gives first-ever approval to fecal transplant therapy
Image source: ©2022 Kalkine Media®

(Adds details on approval, background)


Nov 30 (Reuters) - The U.S. health regulator on Wednesday approved Switzerland-based Ferring Pharmaceuticals' fecal transplant-based therapy to reduce the recurrence of a bacterial infection, making it the first therapy of its kind to be cleared in the United States.

The therapy, Rebyota, targets Clostridium difficile, or C. difficile – a superbug responsible for infections that can cause serious and life-threatening diarrhea. In the United States, the infection is associated with 15,000-30,000 deaths annually.

While this is the first such therapy approved by the Food and Drug Administration (FDA) for recurrent C. difficile infections, fecal microbiota transplants – classified by the regulator as investigational – have long been the standard of care in the U.S. for this condition.

Rebyota is delivered through an enema and works by replenishing good gut bacteria through samples of microbes distilled from faeces of healthy donors.

"As the first FDA-approved fecal microbiota product, (the) action represents an important milestone, as it provides an additional approved option to prevent recurrent CDI," said Peter Marks, director of the agency's Center for Biologics Evaluation and Research.

Besides Ferring, other companies including Seres Therapeutics, which is developing an oral treatment, are working on similar therapies based on fecal microbiota transplantation. (Reporting by Leroy Leo in Bengaluru; Editing by Shailesh Kuber)

Disclaimer

The above content is directly sourced from Reuters under a contractual arrangement. The content is being provided as a convenience and for informational purposes only; and does not constitute an endorsement or approval by Kalkine Media of any of the products, services, or opinions of the organization or individual. The user is apprised that Kalkine Media bears no responsibility for the accuracy, legality, or content of Reuters, any external sites, or for that of subsequent links. The user is requested to contact Reuters directly for answers to questions regarding the content. Please note that Kalkine Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Featured Articles